About Gadeta
Gadeta is a company based in Utrecht (Netherlands) founded in 2015 was acquired by Clade in October 2023. Gadeta has raised $7.82 million across 2 funding rounds from investors including Clade TX, Kite Pharma and European Union. Gadeta operates in a competitive market with competitors including Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Utrecht, Netherlands
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Gadeta
Unlock access to complete
Unlock access to complete
Funding Insights of Gadeta
Gadeta has successfully raised a total of $7.82M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $320.63 thousand completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gadeta
Gadeta has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Clade TX, Kite Pharma and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Knowledge transfer support is provided by Utrecht Holdings.
|
Locked | Locked | Locked | |
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Gadeta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gadeta
Investment portfolio details for Gadeta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gadeta
Detailed financials for Gadeta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gadeta Comparisons
Peer comparison for Gadeta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gadeta
Gadeta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Celgene, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Gadeta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gadeta
Complete news archive for Gadeta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gadeta
Gadeta was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Gadeta is headquartered in Utrecht, Netherlands.
Gadeta is a funded company, having raised a total of $7.82M across 2 funding rounds to date.
Gadeta is focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs). It has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta TCRs with an enhanced anti-cancer reactivity. Its new cell-based anti-cancer product called T Cells engineered to express a defined Gamma Delta TCR (TEGs) that has strong therapeutic potential for combating and eradicating both hematological and solid tumors. This approach utilizes high-affinity gamma delta TCRs expressed on αβ T cells with superior proliferation capacity. Its lead program is in acute myeloid leukemia (AML).
Gadeta's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Gadeta has 6 investors. Key investors include Clade TX, Kite Pharma, European Union, Baxalta, and Utrecht Holdings.